Dr. Akhilesh Vats

Dr. Akhilesh Vats is a pharmaceutical scientist, formulation researcher, founder of ACME Research Solutions, ISEF Qualified Scientist 2026, and Editor-in-Chief at PEXACY International Journal of Pharmaceutical Science. He also serves as an editor at The Witfire Elite Pharma News, where his editorial focus is to make pharma news more useful for serious readers by adding scientific context, regulatory interpretation, market consequence, and business-level meaning.

Iran War Pharma Shock: Why India’s API Dependence Hurts More Than China’s Biotech Lead

Iran War Pharma Shock: Why India’s API Dependence Hurts More Than China’s Biotech Lead

/ Pharma Market Case Studies, Pharma News /

Iran War Pharma Shock: India API Dependence vs China Biotech Chokepoints | Witfire Elite View Witfire Elite Pharma Markets Case Studies Strategy Long Read Pharma Market Case Studies Witfire Elite View Iran War Pharma Shock Why India’s API Dependence Hurts More Than China’s Biotech Lead The Iran war and Strait of Hormuz disruption expose a […]

Iran War Pharma Shock: Why India’s API Dependence Hurts More Than China’s Biotech Lead Read More »

CagriSema Novo Nordisk Obesity Market Analysis

CagriSema May Not Be Enough to Restore Novo Nordisk’s Obesity Lead

/ Pharma Market Case Studies, Pharma News /

Novo Nordisk did not lose momentum because CagriSema is a weak drug. That is too simple. The sharper problem is that CagriSema is being asked to solve a structural challenge: Lilly has already taken the efficacy lead with tirzepatide, is pushing the ceiling higher with retatrutide, and is building a broader obesity portfolio while Novo

CagriSema May Not Be Enough to Restore Novo Nordisk’s Obesity Lead Read More »

Generic semaglutide pens from Indian drugmakers next to branded Ozempic and Wegovy, illustrating India's GLP-1 price war

India’s Generic Ozempic Boom Is a Margin Trap—and the Price Collapse It Started Has Now Reached the US

/ Pharma Market Case Studies, Pharma News /

Witfire Elite View · Pharma Market Case Study · Updated 12 June 2026 The cheapest semaglutide in the world is made in India — and the price collapse it triggered is now reaching the United States. Roughly three months after Novo Nordisk’s core Indian patent expired and more than 40 local drugmakers flooded the market

India’s Generic Ozempic Boom Is a Margin Trap—and the Price Collapse It Started Has Now Reached the US Read More »

Eli Lilly Retatrutide Phase 3 Results at ADA 2026

Eli Lilly Retatrutide Phase 3 Results at ADA 2026

/ Investments, Stock Market /

Eli Lilly Retatrutide Phase 3: 28.3% Weight Loss Pushes Obesity Into a Portfolio War | Witfire Elite View Witfire Elite Pharma News Investments Stock Market Breaking Analysis 28.3 Pharma Market Case Study · Witfire Elite View Eli Lilly Retatrutide Phase 3 Results A 28.3% average weight loss at 80 weeks is the headline. But the

Eli Lilly Retatrutide Phase 3 Results at ADA 2026 Read More »

FTX-6058 and Pociredir: FDA’s PRC2 Risk View Hit a Promising Sickle Cell Drug

FTX-6058 and Pociredir: FDA’s PRC2 Risk View Hit a Promising Sickle Cell Drug

/ FDA & Regulatory Intelligence, FDA & Regulatory Intelligence, Pharma Market Case Studies, Pharma News /

FTX-6058 and Pociredir: FDA’s PRC2 Risk View Hit a Promising Sickle Cell Drug | Witfire Elite View Witfire Elite FDA & Regulatory Case Studies Strategy Breaking Case Study FDA & Regulatory Intelligence Witfire Elite View FTX-6058 and Pociredir FDA’s PRC2 Risk View Hit a Promising Sickle Cell Drug FTX-6058 and Pociredir showed strong early sickle

FTX-6058 and Pociredir: FDA’s PRC2 Risk View Hit a Promising Sickle Cell Drug Read More »

Scroll to Top